Early pharmacological treatment of acute heart failure syndromes: A systematic review of clinical trials
暂无分享,去创建一个
[1] S. Silvers,et al. Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. , 2007, Annals of emergency medicine.
[2] David D. Shin,et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. , 2007, The American journal of cardiology.
[3] E. Vanoli,et al. Istaroxime: a new luso-inotropic agent for heart failure. , 2007, The American journal of cardiology.
[4] David D. Shin,et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial , 2007, Acute cardiac care.
[5] P. Seferovic,et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. , 2006, European heart journal.
[6] Nancy M Albert,et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. , 2006, JAMA.
[7] M. Nieminen,et al. Evidence-based use of levosimendan in different clinical settings. , 2006, European heart journal.
[8] A. Boyle,et al. Large volume ultrafiltration for acute decompensated heart failure using standard peripheral intravenous catheters. , 2006, Journal of cardiac failure.
[9] M. Gheorghiade,et al. Contemporary Use of Digoxin in the Management of Cardiovascular Disorders , 2006, Circulation.
[10] J. Moran,et al. Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis , 2006, The Lancet.
[11] M. Mehra. Optimizing outcomes in the patient with acute decompensated heart failure. , 2006, American heart journal.
[12] R. Fernandez,et al. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. , 2005, JAMA.
[13] Luigi Tavazzi,et al. Acute Heart Failure Syndromes: Current State and Framework for Future Research , 2005, Circulation.
[14] R. Bonow,et al. Neurohormonal inhibition in heart failure: insights from recent clinical trials. , 2005, The American journal of cardiology.
[15] F. Fedele,et al. Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization. , 2005, The American journal of cardiology.
[16] P. Sobotka,et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. , 2005, Journal of the American College of Cardiology.
[17] R. Bourge,et al. Ultrafiltration: a new approach toward mechanical diuresis in heart failure. , 2005, Journal of the American College of Cardiology.
[18] V. Mitrović,et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. , 2005, American heart journal.
[19] M. Gheorghiade,et al. Vasopressin antagonism in heart failure. , 2005, Journal of the American College of Cardiology.
[20] L. Tavazzi,et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. , 2005, European heart journal.
[21] Gerasimos Filippatos,et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. , 2005, The American journal of cardiology.
[22] M. Gheorghiade,et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. , 2005, The American journal of cardiology.
[23] K. Adams,et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, Journal of the American College of Cardiology.
[24] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[25] R. Califf,et al. Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study , 2005, Circulation.
[26] W. Peacock. Morphine for Acute Decompensated Heart Failure: Valuable Adjunct or a Historical Remnant? , 2005 .
[27] D. DeMets,et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). , 2005, Journal of cardiac failure.
[28] K. Aaronson,et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. , 2005, JAMA.
[29] V. Hasselblad,et al. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. , 2005, Journal of cardiac failure.
[30] I. Jóna,et al. Modulation of Sarcoplasmic Reticulum Function by Na+/K+ Pump Inhibitors with Different Toxicity: Digoxin and PST2744 [(E,Z)-3-((2-Aminoethoxy)imino)androstane-6,17-dione Hydrochloride] , 2005, Journal of Pharmacology and Experimental Therapeutics.
[31] K. Aaronson,et al. Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure , 2005, Circulation.
[32] Eduardo R Perna,et al. Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure. , 2005, International journal of cardiology.
[33] Y. Seino,et al. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. , 2005, Circulation journal : official journal of the Japanese Circulation Society.
[34] W John Boscardin,et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. , 2005, JAMA.
[35] K. Adams,et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.
[36] K. Dickstein,et al. [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[37] Christopher M O'Connor,et al. Risk stratification after hospitalization for decompensated heart failure. , 2004, Journal of cardiac failure.
[38] A. Ferreira,et al. N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.
[39] J. Hollander,et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. , 2004, Journal of the American College of Cardiology.
[40] J. Verbalis,et al. Novel Vasopressin V1A and V2 Antagonist (Conivaptan) Increases Serum Sodium Concentration and Effective Water Clearance in Patients with Hyponatremia , 2004 .
[41] W. Peacock,et al. 368 Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE® Registry , 2004 .
[42] C. O'connor,et al. Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial , 2004 .
[43] E. Adamopoulou,et al. 835-6 The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: Results from the calcium sensitizer or inotrope or none in low output heart failure study (CASINO) , 2004 .
[44] C. O'connor,et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. , 2004, American heart journal.
[45] Peter C Austin,et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.
[46] K. Adams,et al. Risk stratification for in-hospital mortality in heart failure using classification and regression tree (CART) methodology: analysis of 33,046 patients in the ADHERE registry , 2003 .
[47] C. O'connor,et al. Results of a twelve week double-blind, placebo-controlled, multicenter study of oral conivaptan to assess functional capacity in patients with class III chronic heart failure , 2003 .
[48] C. O'connor,et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. , 2003, The American journal of cardiology.
[49] G. Fonarow,et al. Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure , 2003, Circulation.
[50] P. Schwartz,et al. Hemodynamic Effects of a New Inotropic Compound, PST-2744, in Dogs With Chronic Ischemic Heart Failure , 2003, Journal of cardiovascular pharmacology.
[51] B. Lewis,et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. , 2003, Journal of the American College of Cardiology.
[52] N. Freemantle,et al. The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. , 2003, European heart journal.
[53] W. Abraham,et al. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. , 2003, Journal of cardiac failure.
[54] V. Hasselblad,et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). , 2003, Journal of the American College of Cardiology.
[55] H. Krumholz,et al. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. , 2003, Journal of the American College of Cardiology.
[56] Christopher M O'Connor,et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.
[57] M. Packer,et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study , 2003 .
[58] N. Freemantle,et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment , 2003 .
[59] N Freemantle,et al. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.
[60] R. Zimlichman,,et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. , 2003, Journal of the American College of Cardiology.
[61] G. Fonarow. Pharmacologic therapies for acutely decompensated heart failure. , 2002, Reviews in cardiovascular medicine.
[62] J. Cleland,et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.
[63] Alan S Maisel,et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.
[64] C. O'connor,et al. Diuretic resistance predicts mortality in patients with advanced heart failure. , 2002, American heart journal.
[65] James B. Young. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .
[66] S. Gottlieb,et al. BG9719 (CVT-124), an A1 Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy , 2002, Circulation.
[67] M. Gheorghiade,et al. Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients , 2002 .
[68] J. Cleland,et al. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology — WARIS II, ESCAMI, PAFAC, RITZ‐1 and TIME , 2001, European journal of heart failure.
[69] J. Ghali,et al. Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure , 2001 .
[70] J. Feinglass,et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. , 1997, American heart journal.
[71] E. Philbin,et al. Association between diuretic use, clinical response, and death in acute heart failure. , 1997, The American journal of cardiology.
[72] E. J. Brown,et al. The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.
[73] D. Annane,et al. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. , 1996, Circulation.
[74] F. Russel,et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. , 1996, Journal of the American College of Cardiology.
[75] K. Swedberg,et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.
[76] J. McMurray,et al. Plasma Endothelin in Chronic Heart Failure , 1992, Circulation.
[77] J. Rouleau,et al. Elevated Endothelin‐1 in Heart Failure and Loss of Normal Response to Postural Change , 1992, Circulation.
[78] M. Gheorghiade,et al. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. , 1987, Journal of the American College of Cardiology.
[79] J. Cohn,et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. , 1985, Annals of internal medicine.
[80] F. Tristani,et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. , 1982, The New England journal of medicine.
[81] D. Tepper,et al. Characterization and Prognostic Value of Persistent Hyponatremia in Patients With Severe Heart Failure in the ESCAPE Trial , 2008 .
[82] Prakash Deedwania,et al. HFSA 2006 comprehensive heart failure practice guideline , 2006 .
[83] C. Lindsell,et al. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. , 2006, Annals of emergency medicine.
[84] M. Gheorghiade,et al. ACUTE AND CHRONIC THERAPEUTIC IMPACT OF A VASOPRESSIN ANTAGONIST IN CONGESTIVE HEART FAILURE (ACTIV IN CHF) INVESTIGATORS. EFFECTS OF TOLVAPTAN, A VASOPRESSIN ANTAGONIST, IN PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE: A RANDOMIZED CONTROLLED TRIAL , 2004 .
[85] S. Russell,et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. , 2003, American heart journal.
[86] V. Hasselblad,et al. RANDOMIZED INTRAVENOUS TEZOSENTAN STUDY-4 INVESTIGATORS TEZOSENTAN IN PATIENTS WITH ACUTE HEART FAILURE AND ACUTE CORONARY SYNDROMES , 2003 .
[87] J. Ghali,et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. , 2001, Circulation.
[88] M. Gheorghiade,et al. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. , 1989, Journal of the American College of Cardiology.
[89] G. L. Neifeld. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure , 1985 .